期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 334, 期 1-2, 页码 123-125出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2013.08.007
关键词
Inclusion body myositis; IL1 receptor anakinra; Autoimmunity; Inflammatory cytokines; Cyrotoxic T-cells
In sIBM, an inflammatory process mediated by cytotoxic T cells and cytokines in conjunction with a degenerative process, deposits of beta amyloid and misfolded proteins appear to be the main culprits in disease pathogenesis. IL-1 beta may play a key role because it is upregulated in sIBM myofibers, co-localizes with Amyloid Precursor Protein (APP) and promotes the production of APP and amyloid deposits. We performed a small, pilot study to examine whether anakinra, an IL1 receptor antagonist could benefit slBM patients. Four patients with biopsy-proven sIBM received anakinra for a mean period of 7.7 months. No improvement in muscle strength or stabilization was noted in any of the patients based on grip strength and MRC measurements. The treatment failure may be due to insufficiency of anakinra to suppress the intramuscular IL1 the short study period, or the irrelevance of IL1 in the disease process. 2013 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据